Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics is on track for potential FDA approval of its phosphate binder OLC on the upcoming PDUFA date, with a launch to follow. The company's strong financial position and active preparations for launch indicate confidence in its potential success. Overall, Unicycive Therapeutics is poised to potentially address unmet medical needs in the kidney disease space and deliver value to shareholders.

Unicycive Therapeutics is facing multiple delays in the launch of its two key product candidates, and in order to meet its projected launch timelines, the company must successfully pass an FDA inspection and resubmit its NDA for both candidates, resulting in a potential Class I review with and earlier PDUFA action date. However, with a recent second CRL for OLC and the possibility of another delay due to site inspection findings, there is significant risk and uncertainty surrounding the company's ability to commercialize its products by 2027. This has resulted in a decrease in the company's target price and a negative outlook, as reflected in its recent earnings in line with estimates and increased OpEx forecasts.